Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history

European Journal of Haematology

Volumn 94, Issue 1, 2015, Pages 31-36

  Gangat, Naseema ^a   Wassie, Emnet A ^a   Lasho, Terra L ^a   Finke, Christy ^a   Ketterling, Rhett P ^a   Hanson, Curtis A ^a   Pardanani, Animesh ^a   Wolanskyj, Alexandra P ^a   Maffioli, Margherita ^b   Casalone, Rosario ^b   Passamonti, Francesco ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Calreticulin; Essential thrombocythemia; Janus kinase 2; Mutation; Thrombosis

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADULT; AGE; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MPL GENE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; THROMBOCYTHEMIA; THROMBOSIS; VEIN THROMBOSIS; WILD TYPE; ADOLESCENT; AGED; COMPLICATION; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CALRETICULIN; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTORS, THROMBOPOIETIN; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; YOUNG ADULT;

EID: 84922935914     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12389     Document Type: Article

References (10)

1. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011;29:3179-84. 10.1200/JCO.2010.34.5298.
2. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012;120:1197-201. 10.1182/blood-2012-01-403279.
3. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-33; quiz 252. 10.1182/blood-2012-07-444067.
4. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-90. 10.1056/NEJMoa1311347.
5. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-405.
6. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi A. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013;123:1552-5.
7. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013;123:1544-51.
8. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014. doi:10.1038/leu.2014.3. [Epub ahead of print]
9. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.